ES2232944T3 - Leptina como un inhibidor de la proliferacion de celulas tumorales. - Google Patents

Leptina como un inhibidor de la proliferacion de celulas tumorales.

Info

Publication number: ES2232944T3
Authority: ES; Spain
Prior art keywords: leptin; insulin; cells; cell proliferation; active
Prior art date: 1997-04-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES98917580T

Other languages

English (en)

Spanish (es)

Inventor

Dalit Barkan

Batya Cohen

Menachem Rubinstein

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Yeda Research and Development Co Ltd

Original Assignee

Yeda Research and Development Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-29

Filing date

1998-04-26

Publication date

2005-06-01

1998-04-26 Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd

2005-06-01 Application granted granted Critical

2005-06-01 Publication of ES2232944T3 publication Critical patent/ES2232944T3/es

2018-04-26 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

230000035755 proliferation Effects 0.000 title claims description 10
210000004881 tumor cell Anatomy 0.000 title claims description 7
239000003112 inhibitor Substances 0.000 title description 6
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims abstract description 103
102000016267 Leptin Human genes 0.000 claims abstract description 102
108010092277 Leptin Proteins 0.000 claims abstract description 102
229940039781 leptin Drugs 0.000 claims abstract description 99
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 58
230000004663 cell proliferation Effects 0.000 claims description 34
102000004877 Insulin Human genes 0.000 claims description 29
108090001061 Insulin Proteins 0.000 claims description 29
229940125396 insulin Drugs 0.000 claims description 29
108010019813 leptin receptors Proteins 0.000 claims description 18
230000005764 inhibitory process Effects 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 14
206010006187 Breast cancer Diseases 0.000 claims description 11
208000026310 Breast neoplasm Diseases 0.000 claims description 11
239000012634 fragment Substances 0.000 claims description 11
102000037865 fusion proteins Human genes 0.000 claims description 9
108020001507 fusion proteins Proteins 0.000 claims description 9
239000000018 receptor agonist Substances 0.000 claims description 9
229940044601 receptor agonist Drugs 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 8
239000013543 active substance Substances 0.000 claims description 6
229940079593 drug Drugs 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 4
241000282412 Homo Species 0.000 claims description 3
201000008275 breast carcinoma Diseases 0.000 claims description 3
102000005861 leptin receptors Human genes 0.000 claims description 3
206010028980 Neoplasm Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 45
239000012091 fetal bovine serum Substances 0.000 description 22
108090000623 proteins and genes Proteins 0.000 description 22
108091003079 Bovine Serum Albumin Proteins 0.000 description 21
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 21
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 21
102000004169 proteins and genes Human genes 0.000 description 21
235000018102 proteins Nutrition 0.000 description 20
108090000765 processed proteins & peptides Proteins 0.000 description 18
102100031775 Leptin receptor Human genes 0.000 description 16
108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 13
102000009433 Insulin Receptor Substrate Proteins Human genes 0.000 description 13
241001529936 Murinae Species 0.000 description 13
235000001014 amino acid Nutrition 0.000 description 13
230000000694 effects Effects 0.000 description 13
238000010186 staining Methods 0.000 description 13
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 12
239000013078 crystal Substances 0.000 description 12
150000001413 amino acids Chemical class 0.000 description 11
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 10
-1 Leu Chemical compound 0.000 description 10
102000004196 processed proteins & peptides Human genes 0.000 description 10
125000000539 amino acid group Chemical group 0.000 description 9
238000000034 method Methods 0.000 description 9
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
230000026731 phosphorylation Effects 0.000 description 7
238000006366 phosphorylation reaction Methods 0.000 description 7
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
230000012010 growth Effects 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
108020004414 DNA Proteins 0.000 description 5
210000000601 blood cell Anatomy 0.000 description 5
230000014509 gene expression Effects 0.000 description 5
239000003102 growth factor Substances 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
102000004127 Cytokines Human genes 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 4
101000871017 Homo sapiens Growth factor receptor-bound protein 2 Proteins 0.000 description 4
239000002253 acid Substances 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
102000003746 Insulin Receptor Human genes 0.000 description 3
108010001127 Insulin Receptor Proteins 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
210000001789 adipocyte Anatomy 0.000 description 3
239000000556 agonist Substances 0.000 description 3
125000003275 alpha amino acid group Chemical group 0.000 description 3
230000037396 body weight Effects 0.000 description 3
201000008274 breast adenocarcinoma Diseases 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
230000037406 food intake Effects 0.000 description 3
235000012631 food intake Nutrition 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
230000008747 mitogenic response Effects 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
102000009465 Growth Factor Receptors Human genes 0.000 description 2
108010009202 Growth Factor Receptors Proteins 0.000 description 2
101001063991 Homo sapiens Leptin Proteins 0.000 description 2
102000004388 Interleukin-4 Human genes 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
102000000585 Interleukin-9 Human genes 0.000 description 2
108010002335 Interleukin-9 Proteins 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
108020005187 Oligonucleotide Probes Proteins 0.000 description 2
241000157426 Pernis Species 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000004927 fusion Effects 0.000 description 2
102000049953 human LEP Human genes 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000002297 mitogenic effect Effects 0.000 description 2
230000035407 negative regulation of cell proliferation Effects 0.000 description 2
239000002751 oligonucleotide probe Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
230000004044 response Effects 0.000 description 2
239000012679 serum free medium Substances 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000021 stimulant Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
239000000758 substrate Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
NTAZNGWBXRVEDJ-FXQIFTODSA-N Arg-Asp-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NTAZNGWBXRVEDJ-FXQIFTODSA-N 0.000 description 1
VDBKFYYIBLXEIF-GUBZILKMSA-N Arg-Gln-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VDBKFYYIBLXEIF-GUBZILKMSA-N 0.000 description 1
BNODVYXZAAXSHW-IUCAKERBSA-N Arg-His Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 BNODVYXZAAXSHW-IUCAKERBSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
GMRGSBAMMMVDGG-GUBZILKMSA-N Asn-Arg-Arg Chemical compound C(C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)CN=C(N)N GMRGSBAMMMVDGG-GUBZILKMSA-N 0.000 description 1
BZMWJLLUAKSIMH-FXQIFTODSA-N Asn-Glu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BZMWJLLUAKSIMH-FXQIFTODSA-N 0.000 description 1
FBODFHMLALOPHP-GUBZILKMSA-N Asn-Lys-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O FBODFHMLALOPHP-GUBZILKMSA-N 0.000 description 1
ZYPWIUFLYMQZBS-SRVKXCTJSA-N Asn-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N ZYPWIUFLYMQZBS-SRVKXCTJSA-N 0.000 description 1
XAJRHVUUVUPFQL-ACZMJKKPSA-N Asp-Glu-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XAJRHVUUVUPFQL-ACZMJKKPSA-N 0.000 description 1
GHODABZPVZMWCE-FXQIFTODSA-N Asp-Glu-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O GHODABZPVZMWCE-FXQIFTODSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
SOBBAYVQSNXYPQ-ACZMJKKPSA-N Gln-Asn-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O SOBBAYVQSNXYPQ-ACZMJKKPSA-N 0.000 description 1
TWHDOEYLXXQYOZ-FXQIFTODSA-N Gln-Asn-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N TWHDOEYLXXQYOZ-FXQIFTODSA-N 0.000 description 1
YGNPTRVNRUKVLA-DCAQKATOSA-N Gln-Met-Met Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCC(=O)N)N YGNPTRVNRUKVLA-DCAQKATOSA-N 0.000 description 1
XEKAJTCACGEBOK-KKUMJFAQSA-N Glu-Met-Phe Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N XEKAJTCACGEBOK-KKUMJFAQSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
AAHSHTLISQUZJL-QSFUFRPTSA-N Gly-Ile-Ile Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AAHSHTLISQUZJL-QSFUFRPTSA-N 0.000 description 1
ZOTGXWMKUFSKEU-QXEWZRGKSA-N Gly-Ile-Met Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(O)=O ZOTGXWMKUFSKEU-QXEWZRGKSA-N 0.000 description 1
OMNVOTCFQQLEQU-CIUDSAMLSA-N His-Asn-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OMNVOTCFQQLEQU-CIUDSAMLSA-N 0.000 description 1
SWSVTNGMKBDTBM-DCAQKATOSA-N His-Gln-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N SWSVTNGMKBDTBM-DCAQKATOSA-N 0.000 description 1
VHOLZZKNEBBHTH-YUMQZZPRSA-N His-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 VHOLZZKNEBBHTH-YUMQZZPRSA-N 0.000 description 1
IDQNVIWPPWAFSY-AVGNSLFASA-N His-His-Gln Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(N)=O)C(O)=O IDQNVIWPPWAFSY-AVGNSLFASA-N 0.000 description 1
BXOLYFJYQQRQDJ-MXAVVETBSA-N His-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CN=CN1)N BXOLYFJYQQRQDJ-MXAVVETBSA-N 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
CDGLBYSAZFIIJO-RCOVLWMOSA-N Ile-Gly-Gly Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O CDGLBYSAZFIIJO-RCOVLWMOSA-N 0.000 description 1
KLJKJVXDHVUMMZ-KKPKCPPISA-N Ile-Phe-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N KLJKJVXDHVUMMZ-KKPKCPPISA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
WXDRGWBQZIMJDE-ULQDDVLXSA-N Leu-Phe-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O WXDRGWBQZIMJDE-ULQDDVLXSA-N 0.000 description 1
MJWVXZABPOKJJF-ACRUOGEOSA-N Leu-Phe-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MJWVXZABPOKJJF-ACRUOGEOSA-N 0.000 description 1
UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
UIIMIKFNIYPDJF-WDSOQIARSA-N Leu-Trp-Met Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)[C@@H](N)CC(C)C)=CNC2=C1 UIIMIKFNIYPDJF-WDSOQIARSA-N 0.000 description 1
WPIKRJDRQVFRHP-TUSQITKMSA-N Leu-Trp-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O WPIKRJDRQVFRHP-TUSQITKMSA-N 0.000 description 1
OVIVOCSURJYCTM-GUBZILKMSA-N Lys-Asp-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OVIVOCSURJYCTM-GUBZILKMSA-N 0.000 description 1
ALGGDNMLQNFVIZ-SRVKXCTJSA-N Lys-Lys-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N ALGGDNMLQNFVIZ-SRVKXCTJSA-N 0.000 description 1
DZMGFGQBRYWJOR-YUMQZZPRSA-N Met-Pro Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O DZMGFGQBRYWJOR-YUMQZZPRSA-N 0.000 description 1
XIGAHPDZLAYQOS-SRVKXCTJSA-N Met-Pro-Pro Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 XIGAHPDZLAYQOS-SRVKXCTJSA-N 0.000 description 1
UYDDNEYNGGSTDW-OYDLWJJNSA-N Met-Trp-Trp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N UYDDNEYNGGSTDW-OYDLWJJNSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
FRMKIPSIZSFTTE-HJOGWXRNSA-N Phe-Tyr-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O FRMKIPSIZSFTTE-HJOGWXRNSA-N 0.000 description 1
IPVPGAADZXRZSH-RNXOBYDBSA-N Phe-Tyr-Trp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O IPVPGAADZXRZSH-RNXOBYDBSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
AIOWVDNPESPXRB-YTWAJWBKSA-N Pro-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2)O AIOWVDNPESPXRB-YTWAJWBKSA-N 0.000 description 1
GZNYIXWOIUFLGO-ZJDVBMNYSA-N Pro-Thr-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZNYIXWOIUFLGO-ZJDVBMNYSA-N 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
JDZPLYBLBIKFHJ-UHFFFAOYSA-N Sulfamoyldapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1S(N)(=O)=O JDZPLYBLBIKFHJ-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
WJKJJGXZRHDNTN-UWVGGRQHSA-N Tyr-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 WJKJJGXZRHDNTN-UWVGGRQHSA-N 0.000 description 1
CGDZGRLRXPNCOC-SRVKXCTJSA-N Tyr-Cys-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CGDZGRLRXPNCOC-SRVKXCTJSA-N 0.000 description 1
ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
CELJCNRXKZPTCX-XPUUQOCRSA-N Val-Gly-Ala Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O CELJCNRXKZPTCX-XPUUQOCRSA-N 0.000 description 1
AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001621 anti-mitogenic effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000008827 biological function Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
230000009702 cancer cell proliferation Effects 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000002987 choroid plexus Anatomy 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
108010004073 cysteinylcysteine Proteins 0.000 description 1
102000003675 cytokine receptors Human genes 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000007783 downstream signaling Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
230000014101 glucose homeostasis Effects 0.000 description 1
125000003827 glycol group Chemical group 0.000 description 1
108010028295 histidylhistidine Proteins 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
108010085203 methionylmethionine Proteins 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
239000000047 product Substances 0.000 description 1
230000009465 prokaryotic expression Effects 0.000 description 1
230000004952 protein activity Effects 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
238000004350 spin decoupling difference spectroscopy Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000035924 thermogenesis Effects 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000563 toxic property Toxicity 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
238000005406 washing Methods 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ES98917580T 1997-04-29 1998-04-26 Leptina como un inhibidor de la proliferacion de celulas tumorales. Expired - Lifetime ES2232944T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL12073397A IL120733A0 (en)	1997-04-29	1997-04-29	Leptin as an inhibitor of cell proliferation
IL12073397		1997-04-29

Publications (1)

Publication Number	Publication Date
ES2232944T3 true ES2232944T3 (es)	2005-06-01

Family

ID=11070075

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES98917580T Expired - Lifetime ES2232944T3 (es)	1997-04-29	1998-04-26	Leptina como un inhibidor de la proliferacion de celulas tumorales.

Country Status (26)

Country	Link
US (1)	US7109159B1 (no)
EP (1)	EP0981365B1 (no)
JP (1)	JP4330662B2 (no)
KR (1)	KR100507731B1 (no)
CN (1)	CN1168497C (no)
AR (1)	AR012626A1 (no)
AT (1)	ATE283702T1 (no)
AU (1)	AU742927B2 (no)
BG (1)	BG63490B1 (no)
CA (1)	CA2288238A1 (no)
CZ (1)	CZ299872B6 (no)
DE (1)	DE69827942T2 (no)
EA (1)	EA002353B1 (no)
EE (1)	EE04801B1 (no)
ES (1)	ES2232944T3 (no)
HK (1)	HK1028350A1 (no)
HU (1)	HUP0002427A3 (no)
IL (2)	IL120733A0 (no)
NO (1)	NO322304B1 (no)
NZ (1)	NZ500589A (no)
PL (1)	PL195275B1 (no)
PT (1)	PT981365E (no)
SK (1)	SK284848B6 (no)
UA (1)	UA66793C2 (no)
WO (1)	WO1998048831A1 (no)
ZA (1)	ZA983608B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7208572B2 (en)	1998-08-21	2007-04-24	Albany Medical College	Leptin-related peptides
US6777388B1 (en)	1998-08-21	2004-08-17	Clf Medical Technology Acceleration Program, Inc.	Leptin-related peptides
US20050272652A1 (en)	1999-03-29	2005-12-08	Gault Victor A	Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
IL132312A0 (en) *	1999-09-05	2001-03-19	Yeda Res & Dev	Use of leptin in inhibition of endothelial cell proliferation
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
CN103897066A (zh)	2004-02-11	2014-07-02	安米林药品有限责任公司	具有可选择特性的杂合多肽
US7863240B2 (en) *	2004-10-08	2011-01-04	Enzo Therapeutics, Inc.	Methods and uses of leptin in hepatocellular carcinoma
US8969291B2 (en)	2004-10-08	2015-03-03	Enzo Therapeutics, Inc.	Methods for decreasing leptin levels or activity for treating inflammation
EP2392595A1 (en)	2005-02-11	2011-12-07	Amylin Pharmaceuticals Inc.	GIP analog and hybrid polypeptides with selectable properties
US8263545B2 (en)	2005-02-11	2012-09-11	Amylin Pharmaceuticals, Inc.	GIP analog and hybrid polypeptides with selectable properties
EP2330125A3 (en)	2005-08-11	2012-12-12	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
EP1922336B1 (en)	2005-08-11	2012-11-21	Amylin Pharmaceuticals, LLC	Hybrid polypeptides with selectable properties
US8227408B2 (en) *	2005-09-07	2012-07-24	Neurotez, Inc.	Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US8497240B2 (en)	2006-08-17	2013-07-30	Amylin Pharmaceuticals, Llc	DPP-IV resistant GIP hybrid polypeptides with selectable properties
NZ620606A (en)	2008-02-08	2015-08-28	Ambrx Inc	Modified leptin polypeptides and their uses
WO2009143380A2 (en) *	2008-05-21	2009-11-26	Neurotez, Inc.	Methods for treating progressive cognitive disorders related to neurofibrillary tangles
AU2009313562B2 (en) *	2008-11-04	2012-11-15	Neurotez, Inc.	Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
WO2010146059A2 (en)	2009-06-16	2010-12-23	F. Hoffmann-La Roche Ag	Biomarkers for igf-1r inhibitor therapy
TWI824372B (zh)	2015-10-12	2023-12-01	美商再生元醫藥公司	活化瘦素受體的抗原結合蛋白
KR102563568B1 (ko)	2016-11-08	2023-08-04	리제너론 파마슈티칼스 인코포레이티드	렙틴 수용체에 길항하는 항원-결합 단백질
CA3084385A1 (en)	2017-12-18	2019-06-27	Regeneron Pharmaceuticals, Inc.	Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
KR20200141461A (ko)	2018-04-06	2020-12-18	리제너론 파마슈티칼스 인코포레이티드	렙틴 수용체 작용제 항체를 사용한 치료 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2225454A1 (en) *	1995-06-30	1997-01-23	Thomas Wesley Stephens	Methods for treating diabetes
JPH11512296A (ja) *	1995-09-19	1999-10-26	イーライ・リリー・アンド・カンパニー	医療用タンパク質をコードしているｄｎａ
ES2260784T3 (es) *	1996-01-23	2006-11-01	Indevus Pharmaceuticals, Inc.	Metodos de utilizacion del gen obese y su producto genico para estimular el desarrolo hematopoyetico.

1997
- 1997-04-29 IL IL12073397A patent/IL120733A0/xx unknown
1998
- 1998-04-26 AT AT98917580T patent/ATE283702T1/de active
- 1998-04-26 PL PL98336582A patent/PL195275B1/pl not_active IP Right Cessation
- 1998-04-26 EA EA199900981A patent/EA002353B1/ru not_active IP Right Cessation
- 1998-04-26 CN CNB988066920A patent/CN1168497C/zh not_active Expired - Fee Related
- 1998-04-26 PT PT98917580T patent/PT981365E/pt unknown
- 1998-04-26 AU AU70762/98A patent/AU742927B2/en not_active Ceased
- 1998-04-26 UA UA99116415A patent/UA66793C2/uk unknown
- 1998-04-26 EE EEP199900510A patent/EE04801B1/xx not_active IP Right Cessation
- 1998-04-26 ES ES98917580T patent/ES2232944T3/es not_active Expired - Lifetime
- 1998-04-26 CZ CZ0384899A patent/CZ299872B6/cs not_active IP Right Cessation
- 1998-04-26 WO PCT/IL1998/000196 patent/WO1998048831A1/en active IP Right Grant
- 1998-04-26 HU HU0002427A patent/HUP0002427A3/hu unknown
- 1998-04-26 JP JP54678798A patent/JP4330662B2/ja not_active Expired - Fee Related
- 1998-04-26 DE DE69827942T patent/DE69827942T2/de not_active Expired - Lifetime
- 1998-04-26 EP EP98917580A patent/EP0981365B1/en not_active Expired - Lifetime
- 1998-04-26 CA CA002288238A patent/CA2288238A1/en not_active Abandoned
- 1998-04-26 KR KR10-1999-7009705A patent/KR100507731B1/ko not_active IP Right Cessation
- 1998-04-26 NZ NZ500589A patent/NZ500589A/xx not_active IP Right Cessation
- 1998-04-26 US US09/403,897 patent/US7109159B1/en not_active Expired - Fee Related
- 1998-04-26 SK SK1471-99A patent/SK284848B6/sk not_active IP Right Cessation
- 1998-04-29 ZA ZA983608A patent/ZA983608B/xx unknown
- 1998-04-29 AR ARP980102003A patent/AR012626A1/es unknown
1999
- 1999-10-25 BG BG103832A patent/BG63490B1/bg unknown
- 1999-10-28 NO NO19995267A patent/NO322304B1/no not_active IP Right Cessation
- 1999-10-28 IL IL132633A patent/IL132633A/en not_active IP Right Cessation
2000
- 2000-12-07 HK HK00107866A patent/HK1028350A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
EA199900981A1 (ru)	2000-04-24
EE04801B1 (et)	2007-04-16
KR20010012080A (ko)	2001-02-15
PL195275B1 (pl)	2007-08-31
EA002353B1 (ru)	2002-04-25
US7109159B1 (en)	2006-09-19
HK1028350A1 (en)	2001-02-16
BG63490B1 (bg)	2002-03-29
AR012626A1 (es)	2000-11-08
SK147199A3 (en)	2000-06-12
JP4330662B2 (ja)	2009-09-16
HUP0002427A2 (hu)	2000-12-28
CN1168497C (zh)	2004-09-29
EE9900510A (et)	2000-06-15
JP2001524968A (ja)	2001-12-04
DE69827942D1 (de)	2005-01-05
AU742927B2 (en)	2002-01-17
EP0981365A1 (en)	2000-03-01
PL336582A1 (en)	2000-07-03
NO995267L (no)	1999-12-28
ZA983608B (en)	1998-11-02
CN1261802A (zh)	2000-08-02
CZ384899A3 (cs)	2000-06-14
NO995267D0 (no)	1999-10-28
IL120733A0 (en)	1997-08-14
NO322304B1 (no)	2006-09-11
HUP0002427A3 (en)	2003-02-28
NZ500589A (en)	2001-03-30
DE69827942T2 (de)	2005-12-08
CA2288238A1 (en)	1998-11-05
AU7076298A (en)	1998-11-24
PT981365E (pt)	2005-03-31
UA66793C2 (uk)	2004-06-15
SK284848B6 (sk)	2006-01-05
ATE283702T1 (de)	2004-12-15
BG103832A (en)	2000-10-31
EP0981365B1 (en)	2004-12-01
WO1998048831A1 (en)	1998-11-05
CZ299872B6 (cs)	2008-12-17
KR100507731B1 (ko)	2005-08-10
IL132633A (en)	2007-07-04

Publication	Publication Date	Title
ES2232944T3 (es)	2005-06-01	Leptina como un inhibidor de la proliferacion de celulas tumorales.
KR102357275B1 (ko)	2022-02-03	심부전을 치료하기 위한 뉴레귤린의 연장 방출
JP2019056013A (ja)	2019-04-11	ヒト成長ホルモン類似体を用いた小児成長ホルモン分泌不全症の治療
US20110195896A1 (en)	2011-08-11	Isoform-specific insulin analogues
PT754048E (pt)	2002-01-30	Tratamento do sindrome de insensibilidade a hormona do crescimento
KR20020010920A (ko)	2002-02-06	각질세포 성장 인자-2 제제
CA2494542A1 (en)	2003-11-13	Preventing secondary lymphedema with vegf-d dna
KR20080021588A (ko)	2008-03-07	메카노 성장 인자 펩티드 및 이들의 용도
US20090088374A1 (en)	2009-04-02	Novel use
KR100361717B1 (ko)	2003-07-07	조골세포증식인자
MXPA99009972A (en)	2000-09-04	Leptin as an inhibitor of tumor cell proliferation
EP3491012A1 (en)	2019-06-05	Treatment of adult growth hormone deficiency with human growth hormone analogues
US20090137465A1 (en)	2009-05-28	Novel use
ES2371032T3 (es)	2011-12-26	Nuevo tratamiento y/o prevención del cáncer y/o la artritis.
ZA200600646B (en)	2007-06-27	Use of human growth hormone in multiple system atrophy